Oppenheimer set a $14.00 price target on Mediwound (NASDAQ:MDWD) in a research note issued to investors on Wednesday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
A number of other analysts have also issued reports on the company. Wells Fargo & Co set a $11.00 target price on Mediwound and gave the company a buy rating in a research report on Wednesday, August 8th. Zacks Investment Research lowered Mediwound from a hold rating to a sell rating in a research report on Wednesday, July 11th. Finally, ValuEngine raised Mediwound from a sell rating to a hold rating in a research report on Friday, June 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $9.79.
Shares of NASDAQ MDWD opened at $6.35 on Wednesday. The company has a market capitalization of $170.40 million, a price-to-earnings ratio of -10.24 and a beta of -0.14. Mediwound has a 52-week low of $3.56 and a 52-week high of $7.35.
Mediwound (NASDAQ:MDWD) last announced its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.05. The company had revenue of $1.03 million for the quarter, compared to analyst estimates of $0.96 million. Mediwound had a negative return on equity of 210.90% and a negative net margin of 783.30%. equities research analysts expect that Mediwound will post -0.71 EPS for the current year.
Several large investors have recently bought and sold shares of the business. Nexthera Capital LP acquired a new position in shares of Mediwound in the second quarter worth $308,000. Renaissance Technologies LLC grew its stake in shares of Mediwound by 10.4% in the second quarter. Renaissance Technologies LLC now owns 130,500 shares of the biopharmaceutical company’s stock worth $900,000 after acquiring an additional 12,300 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of Mediwound by 1.0% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,098,277 shares of the biopharmaceutical company’s stock worth $14,478,000 after acquiring an additional 21,559 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in shares of Mediwound by 19.9% in the first quarter. Wells Fargo & Company MN now owns 121,323 shares of the biopharmaceutical company’s stock worth $631,000 after acquiring an additional 20,134 shares in the last quarter. Institutional investors and hedge funds own 32.13% of the company’s stock.
Mediwound Company Profile
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Featured Article: Leveraged Buyout (LBO)
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.